2024-04-12 08:00 Regulatory
Biovica, active in cancer monitoring, today announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida. If successful, it will further validate the utility of DiviTum TKa as an effective tool for disease monitoring. "The...
2024-04-11 08:00 Regulatory
The Nomination Committee prior to the 2024 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...
2024-03-19 08:00 Regulatory
Biovica, active in blood-based cancer monitoring, has received a positive International Preliminary Report on Patentability (IPRP) covering the use of TKa as a prognostic and monitoring marker in cancer treatment outside the CDK 4/6 inhibitor space, expanding...
2024-03-14 08:00 Regulatory Interim
Several new commercial agreements signed and evidence that DiviTum® TKa significantly improves clinical routines in the USA. Significant events during the third quarter Significant events after the end of the period Webcast:When: 14/3 2024 kl. 15.00...
2024-03-13 08:30 Regulatory
Biovica, active in blood-based cancer monitoring, today announces that a clinical trial, BettER, is being launched at Washington University School of Medicine in St. Louis. The study is aimed at evaluating whether patients with HR+ HER2- metastatic or...
2024-03-12 08:00 Regulatory
Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a biopharmaceutical company enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several work orders, the first...
2024-03-07 08:00 Regulatory
Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a leading tier-1 pharmaceutical company, enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several expected...
2024-01-19 08:30 Regulatory
Biovica, active in cancer monitoring, has signed a collaboration agreement for DiviTum® TKa in Spain and Portugal with the Palex Group, a leading hospital equipment supplier with a proven track record in taking oncology tests and surgical instruments...
2023-12-14 17:20 Regulatory
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND...
2023-12-05 13:00 Regulatory
Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum® TKa will be presented at the world's largest breast cancer symposium, SABCS, in early December. New clinical research for...

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No